GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » 14-Day RSI

Kontafarma China Holdings (HKSE:01312) 14-Day RSI : 45.72 (As of Jun. 01, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-01), Kontafarma China Holdings's 14-Day RSI is 45.72.

The industry rank for Kontafarma China Holdings's 14-Day RSI or its related term are showing as below:

HKSE:01312's 14-Day RSI is ranked worse than
50.26% of 1140 companies
in the Drug Manufacturers industry
Industry Median: 45.61 vs HKSE:01312: 45.72

Competitive Comparison of Kontafarma China Holdings's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kontafarma China Holdings's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's 14-Day RSI falls into.



Kontafarma China Holdings  (HKSE:01312) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kontafarma China Holdings  (HKSE:01312) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Kontafarma China Holdings 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Kontafarma China Holdings (HKSE:01312) Business Description

Traded in Other Exchanges
N/A
Address
30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.
Executives
Ning Bo Bao Shui Qu San Jin Guo Tou Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shan Xi Jiao Tong Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Jian She Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Ren Min Zheng Fu Guo You Zi Chan Jian Du Guan Li Wei Yuan Hui 2201 Interest of corporation controlled by you
Shan Xi Sheng Gao Su Gong Lu Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Guo You Zi Ben Yun Ying You Xian Gong Si Qian Cheng Shan Xi Sheng Guo You Zi Ben Tou Z 2201 Interest of corporation controlled by you
China Health Management Investment Limited 2101 Beneficial owner
Waranty Assets Management (hk) Limited 2201 Interest of corporation controlled by you
Shen Zhen Shi Hua Rong Tai Zi Chan Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Resuccess Investments Limited
Thtf Energy-saving Holdings Limited

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines